Catch me if you can: Phagocytosis and killing avoidance by Cryptococcus neoformans

FEMS Immunology and Medical Microbiology

Volumn 64, Issue 2, 2012, Pages 147-161

  García Rodas, Rocío ^a   Zaragoza, Oscar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cryptococcus neoformans; Intracellular pathogenesis; Macrophages; Phagocytosis

Indexed keywords

OPSONIN; POLYSACCHARIDE;

CELL DIVISION; CELL FUSION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS TRANSMISSION; HUMAN; INTRACELLULAR SURVIVAL; LATENT PERIOD; MACROPHAGE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ANIMALS; CELL LINE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTRACELLULAR SPACE; MACROPHAGES; MICE; PHAGOCYTOSIS;

EID: 84856956876     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00871.x     Document Type: Review

References (113)

1. Alanio A, Desnos-Ollivier M & Dromer F (2011) Dynamics of Cryptococcus neoformans-Macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. mBio 2: e00158-11.
2. Alvarez M & Casadevall A (2006) Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol 16: 2161-2165.
3. Alvarez M & Casadevall A (2007) Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol 8: 16.
4. Alvarez M, Burn T, Luo Y, Pirofski LA & Casadevall A (2009) The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol 9: 51.
5. Bartlett K, Byrnes E, Duncan C et al. (2011) The emergence of Cryptococcus gatti infection on Vancouver Island and expansion in the Pacific Northwest. Cryptococcus from Human Pathogen to Model Yeast (Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A, eds), pp. 313-327. ASM press, Washington, DC.
6. Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A & Scharff MD (2001) Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans Infect Immun 69: 6445-6455.
7. Blackstock R & Murphy JW (1997) Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans Infect Immun 65: 4114-4121.
8. Bliska JB & Casadevall A (2009) Intracellular pathogenic bacteria and fungi - a case of convergent evolution? Nat Rev Microbiol 7: 165-171.
9. Brown SM, Campbell LT & Lodge JK (2007) Cryptococcus neoformans, a fungus under stress. Curr Opin Microbiol 10: 320-325.
10. Carniato A, Scotton PG, Miotti AM & Mengoli C (2009) [Cryptococcus neoformans meningoencephalitis among apparently immunocompetent patients: description of two cases]. Infez Med 17: 41-45.
11. Casadevall A & Perfect JR (1998) Cryptococcus neoformans ASM press, Washington, DC.
12. Chang YC & Kwon-Chung KJ (1999) Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans J Bacteriol 181: 5636-5643.
13. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, Paul-Satyaseela M, Kim KS & Kwon-Chung KJ (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 72: 4985-4995.
14. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F & Dromer F (2009) Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans Infect Immun 77: 120-127.
15. Chaturvedi S & Chaturvedi V (2011) Virulence mechanisms of Cryptococcus gattii: convergence and divergence. Cryptococcus from human pathogen to model yeast (Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A, eds), pp. 189-203. ASM press, Washington, DC.
16. Chaturvedi V, Wong B & Newman SL (1996) Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J Immunol 156: 3836-3840.
17. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK & Kwon-Chung KJ (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14: 755-762.
18. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F & Dromer F (2002) Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 186: 522-530.
19. Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E & Casadevall A (2011) Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog 7: e1002047.
20. Chun CD, Brown JC & Madhani HD (2011) A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans Cell Host Microbe 9: 243-251.
21. Cinatl J, Paluska E, Chudomel V, Malaskova V & Elleder M (1982) Culture of macrophage cell lines from normal mouse bone marrow. Nature 298: 388-389.
22. Cleare W & Casadevall A (1998) The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol 5: 125-129.
23. Cleare W, Cherniak R & Casadevall A (1999) In vitro and in vivo stability of a Cryptococcus neoformans glucuronoxylomannan epitope that elicits protective antibodies. Infect Immun 67: 3096-3107.
24. Del Poeta M (2004) Role of phagocytosis in the virulence of Cryptococcus neoformans Eukaryot Cell 3: 1067-1075.
25. Diamond RD & Bennett JE (1973) Growth of Cryptococcus neoformans within human macrophages in vitro Infect Immun 7: 231-236.
26. Doering TL, Nosanchuk JD, Roberts WK & Casadevall A (1999) Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol 37: 175-181.
27. Drevets DA & Leenen PJ (2000) Leukocyte-facilitated entry of intracellular pathogens into the central nervous system. Microbes Infect 2: 1609-1618.
28. Dromer F, Casadevall A, Perfect JR & Sorrell T (2011) Cryptococcus neoformans: latency and disease. Cryptococcus from Human Pathogen to Model Yeast (Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A, eds), pp. 431-441. ASM press, Washington, DC.
29. Eissenberg LG, Goldman WE & Schlesinger PH (1993) Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med 177: 1605-1611.
30. El Ouazzani H, Achachi L, Belkhiri S, El Ftouh M & Fassy Fihry MT (2009) [Disseminated cryptococcosis in an apparently immunocompetent patient]. Rev Mal Respir 26: 788-793.
31. Feldmesser M, Kress Y, Novikoff P & Casadevall A (2000) Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun 68: 4225-4237.
32. Feldmesser M, Kress Y & Casadevall A (2001a) Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147: 2355-2365.
33. Feldmesser M, Tucker S & Casadevall A (2001b) Intracellular parasitism of macrophages by Cryptococcus neoformans Trends Microbiol 9: 273-278.
34. Forbes IJ & Mackaness GB (1963) Mitosis in macrophages. Lancet 41: 1203-1204.
35. Garcia-Rodas R, Gonzalez-Camacho F, Rodriguez-Tudela JL, Cuenca-Estrella M & Zaragoza O (2011) The interaction between Candida krusei and Murine macrophages results in multiple outcomes, including intracellular survival and escape from killing. Infect Immun 79: 2136-2144.
36. Gates MA & Kozel TR (2006) Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans Infect Immun 74: 3096-3106.
37. Giles SS, Batinic-Haberle I, Perfect JR & Cox GM (2005) Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth. Eukaryot Cell 4: 46-54.
38. Giles SS, Stajich JE, Nichols C, Gerrald QD, Alspaugh JA, Dietrich F & Perfect JR (2006) The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell 5: 1447-1459.
39. Giles SS, Dagenais TR, Botts MR, Keller NP & Hull CM (2009) Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans Infect Immun 77: 3491-3500.
40. Goldman D, Lee SC & Casadevall A (1994) Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 62: 4755-4761.
41. Goldman DL, Lee SC, Mednick AJ, Montella L & Casadevall A (2000) Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 68: 832-838.
42. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski LA, Niang R & Casadevall A (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107: E66.
43. Gomez BL & Nosanchuk JD (2003) Melanin and fungi. Curr Opin Infect Dis 16: 91-96.
44. Grechi J, Marinho-Carvalho M, Zancan P, Cinelli LP, Gomes AM, Rodrigues ML, Nimrichter L & Sola-Penna M (2011) Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages. J Biol Chem 286: 14820-14829.
45. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A (2011) Cryptococcus from human pathogen to model yeast, pp. 646. ASM press, Washington, DC.
46. Hoag KA, Street NE, Huffnagle GB & Lipscomb MF (1995) Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 13: 487-495.
47. Hoag KA, Lipscomb MF, Izzo AA & Street NE (1997) IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 17: 733-739.
48. Howard DH (1965) Intracellular growth of Histoplasma capsulatum J Bacteriol 89: 518-523.
49. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, Lee S & Jong A (2011) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem. doi: 10.1074/jbc.M111.219378.
50. Huffnagle GB (1996) Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol Signals 5: 215-222.
51. Johnston SA & May RC (2010) The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. PLoS Pathog 6: e1001041.
52. Kechichian TB, Shea J & Del Poeta M (2007) Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect Immun 75: 4792-4798.
53. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ & Meyer W (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). P Natl Acad Sci USA 101: 17258-17263.
54. Koguchi Y & Kawakami K (2002) Cryptococcal infection and Th1-Th2 cytokine balance. Int Rev Immunol 21: 423-438.
55. Kozel TR & Gotschlich EC (1982) The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 129: 1675-1680.
56. Kozel TR & Pfrommer GS (1986) Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun 52: 1-5.
57. Kozel TR, Wilson MA, Farrell TP & Levitz SM (1989) Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect Immun 57: 3412-3417.
58. Kozel TR, Tabuni A, Young BJ & Levitz SM (1996) Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun 64: 2336-2338.
59. Lee SC, Kress Y, Zhao ML, Dickson DW & Casadevall A (1995) Cryptococcus neoformans survive and replicate in human microglia. Lab Invest 73: 871-879.
60. Levitz SM (1994) Macrophage-Cryptococcus interactions. Immunol Ser 60: 533-543.
61. Levitz SM (2001) Cryptococcus neoformans: intracellular or extracellular? Trends Microbiol 9: 417-418.
62. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA & Simons ER (1999) Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 67: 885-890.
63. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD & Noble SM (2008) Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans Cell 135: 174-188.
64. Luberto C, Toffaletti DL, Wills EA, Tucker SC, Casadevall A, Perfect JR, Hannun YA & Del Poeta M (2001) Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans Genes Dev 15: 201-212.
65. Luberto C, Martinez-Marino B, Taraskiewicz D et al. (2003) Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans J Clin Invest 112: 1080-1094.
66. Lui G, Lee N, Ip M, Choi KW, Tso YK, Lam E, Chau S, Lai R & Cockram CS (2006) Cryptococcosis in apparently immunocompetent patients. QJM 99: 143-151.
67. Luo Y, Cook E, Fries BC & Casadevall A (2006) Phagocytic efficacy of macrophage-like cells as a function of cell cycle and Fcgamma receptors (FcgammaR) and complement receptor (CR)3 expression. Clin Exp Immunol 145: 380-387.
68. Luo Y, Alvarez M, Xia L & Casadevall A (2008) The outcome of phagocytic cell division with infectious cargo depends on single phagosome formation. PLoS ONE 3: e3219.
69. Ma H & May RC (2010) Mitochondria and the regulation of hypervirulence in the fatal fungal outbreak on Vancouver Island. Virulence 1: 197-201.
70. Ma H, Croudace JE, Lammas DA & May RC (2006) Expulsion of live pathogenic yeast by macrophages. Curr Biol 16: 2156-2160.
71. Ma H, Croudace JE, Lammas DA & May RC (2007) Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol 8: 15.
72. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T & May RC (2009) The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. P Natl Acad Sci USA 106: 12980-12985.
73. Mansour MK & Levitz SM (2002) Interactions of fungi with phagocytes. Curr Opin Microbiol 5: 359-365.
74. McQuiston T & Del Poeta M (2011) The interaction of Cryptococcus neoformans with host macrophages and neutrophils. Cryptococcus from Human Pathogen to Model Yeast (Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A, eds), pp. 373-387. ASM press, Washington, DC.
75. Mitchell TG & Friedman L (1972) In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans Infect Immun 5: 491-498.
76. Monari C, Bistoni F, Casadevall A, Pericolini E, Pietrella D, Kozel TR & Vecchiarelli A (2005) Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J Infect Dis 191: 127-137.
77. Naslund PK, Miller WC & Granger DL (1995) Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun 63: 1298-1304.
78. Netski D & Kozel TR (2002) Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect Immun 70: 2812-2819.
79. Nicola AM, Robertson EJ, Albuquerque P, Derengowski Lda S & Casadevall A (2011) Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. mBio 2: e00167-11.
80. Nussbaum G, Cleare W, Casadevall A, Scharff MD & Valadon P (1997) Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185: 685-694.
81. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chretien F, Heitman J, Dromer F & Nielsen K (2010) Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog 6: e1000953.
82. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG & Chiller TM (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
83. Qin QM, Luo J, Lin X, Pei J, Li L, Ficht TA & de Figueiredo P (2011) Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans PLoS Pathog 7: e1002078.
84. Russell DG & Gordon S (2009) Phagocyte-Pathogen Interactions. Macrophages and the Host Response to Infection. ASM press, Washington, DC.
85. Saha DC, Goldman DL, Shao X et al. (2007) Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 14: 1550-1554.
86. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A & Goldman DL (2005) An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol 175: 3244-3251.
87. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, Kubes P & Mody CH (2010) Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 120: 1683-1693.
88. Shoham S, Huang C, Chen JM, Golenbock DT & Levitz SM (2001) Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 166: 4620-4626.
89. Small JM & Mitchell TG (1989) Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A. Infect Immun 57: 3751-3756.
90. Srikanta D, Yang M, Williams W & Doering TL (2011) A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infection. PLoS ONE 6: e22773.
91. Stano P, Williams V, Villani M, Cymbalyuk ES, Qureshi A, Huang Y, Morace G, Luberto C, Tomlinson S & Del Poeta M (2009) App1: an antiphagocytic protein that binds to complement receptors 3 and 2. J Immunol 182: 84-91.
92. Steenbergen JN, Shuman HA & Casadevall A (2001) Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. P Natl Acad Sci USA 98: 15245-15250.
93. Steenbergen JN, Nosanchuk JD, Malliaris SD & Casadevall A (2003) Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum Infect Immun 71: 4862-4872.
94. Syme RM, Spurrell JC, Amankwah EK, Green FH & Mody CH (2002) Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect Immun 70: 5972-5981.
95. Taborda CP & Casadevall A (2002) CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans Immunity 16: 791-802.
96. Tucker SC & Casadevall A (2002) Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. P Natl Acad Sci USA 99: 3165-3170.
97. van Duin D, Casadevall A & Nosanchuk JD (2002) Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 46: 3394-3400.
98. Vecchiarelli A, Dottorini M, Pietrella D, Monari C, Retini C, Todisco T & Bistoni F (1994) Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol 11: 130-137.
99. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR & Heitman J (2009) Spores as infectious propagules of Cryptococcus neoformans Infect Immun 77: 4345-4355.
100. Vetvicka V, Thornton BP & Ross GD (1996) Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98: 50-61.
101. Voelz K, Lammas DA & May RC (2009) Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans Infect Immun 77: 3450-3457.
102. Voelz K, Johnston SA, Rutherford JC & May RC (2010) Automated analysis of cryptococcal macrophage parasitism using GFP-tagged cryptococci. PLoS ONE 5: e15968.
103. Voelz K, Johnston SA & May RC (2011) Intracellular replication and exit strategies. Cryptococcus from Human Pathogen to Model Yeast (Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR & Casadevall A, eds), pp. 441-451. ASM press, Washington, DC.
104. Weiss G, Bogdan C & Hentze MW (1997) Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 158: 420-425.
105. Westermann J, Ronneberg S, Fritz FJ & Pabst R (1989) Proliferation of macrophage subpopulations in the adult rat: comparison of various lymphoid organs. J Leukoc Biol 46: 263-269.
106. Williamson PR (1994) Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase. J Bacteriol 176: 656-664.
107. Woods JP (2003) Knocking on the right door and making a comfortable home: Histoplasma capsulatum intracellular pathogenesis. Curr Opin Microbiol 6: 327-331.
108. Yauch LE, Mansour MK, Shoham S, Rottman JB & Levitz SM (2004) Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo Infect Immun 72: 5373-5382.
109. Zaragoza O, Taborda CP & Casadevall A (2003) The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol 33: 1957-1967.
110. Zaragoza O, Alvarez M, Telzak A, Rivera J & Casadevall A (2007) The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun 75: 2729-2739.
111. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodriguez-Tudela JL & Casadevall A (2008) Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol 10: 2043-2057.
112. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E & Casadevall A (2009) The capsule of the fungal pathogen Cryptococcus neoformans Adv Appl Microbiol 68: 133-216.
113. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL & Casadevall A (2010) Fungal cell gigantism during mammalian infection. PLoS Pathog 6: e1000945.